Docetaxel, Cisplatin, and Fluorouracil; Docetaxel and Cisplatin; and Epirubicin, Cisplatin, and Fluorouracil As Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial of the Swiss Group for Clinical Cancer Research

Roth, Arnaud; Fazio, Nicola; Stupp, Roger; Falk, Stephen; Bernhard, Jürg; Saletti, Piercarlo; Köberle, Dieter; Borner, Markus; Rufibach, Kaspar; Maibach, Rudolf; Wernli, Martin; Leslie, M.D.; Glynne‐Jones, Robert; Widmer, Lukas A.; Seymour, Michel; Braud, Filippo de

doi:10.1200/jco.2006.08.0135

Cited by 211 publications

(162 citation statements)

References 22 publications

Supporting

Mentioning

149

Contrasting

Unclassified

Order By: Relevance

“…In regard to the clinical activities, the addition of 5-Fu had been demonstrated a confirmed higher ORR than TP alone (37-43% vs 18-26%) (Ajani, et al, 2005;Roth, et al, 2007). The ORRs in our study were less impressive compared with the previous data (20.0% vs 19.7%).…”

Section: Discussioncontrasting

confidence: 56%

Efficacy of Taxane-Based Regimens in a First-line Setting for Recurrent and/or Metastatic Chinese Patients with Esophageal Cancer

Jiang

Liao²,

Rong³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 56%

Efficacy of Taxane-Based Regimens in a First-line Setting for Recurrent and/or Metastatic Chinese Patients with Esophageal Cancer

Jiang

Liao²,

Rong³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…A similarly designed weekly docetaxel-based triplet was associated with a comparable toxicity profile and encouraging efficacy in a population in which almost half of the patients had locally advanced disease only (Lorenzen et al, 2007). Other studies have shown similar trends for greater activity from a triplet regimen than from a doublet regimen in advanced gastric cancer (Ajani et al, 2005;Roth et al, 2007). In other diseases, such as colorectal cancer or breast cancer, it is common to sequence doublet therapy or even monotherapy regimens.…”

Section: Discussionmentioning

confidence: 77%

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial

et al. 2010

View full text Add to dashboard Cite

BACKGROUND: Docetaxel administered 3-weekly with cisplatin and 5-fluorouracil leads to better survival than does standard therapy in patients with oesophagogastric cancer, but leads to high rates of haematological toxicity. Weekly docetaxel is associated with less haematological toxicity. This randomised phase II study tested weekly docetaxel-based combination chemotherapy regimens, with the aim of maintaining their activity while reducing toxicity. METHODS: Patients with histologically confirmed metastatic oesophageal or gastric carcinoma were randomised to receive weekly docetaxel (30 mg m À2 ) on days 1 and 8, cisplatin (60 mg m À2 ) on day 1, and 5-fluorouracil (200 mg m À2 per day) continuously, every 3 weeks (weekly TCF, wTCF); or docetaxel (30 mg m À2 ) on days 1 and 8 and capecitabine (1600 mg m À2 per day) on days 1 -14, every 3 weeks (weekly TX, wTX). RESULTS: A total of 106 patients were enrolled (wTCF, n ¼ 50; wTX, n ¼ 56). Response rates, the primary end point, were 47% with wTCF and 26% with wTX. Rates of febrile neutropenia were low in each arm. Median progression-free and overall survival times were 5.9 and 11.2 months for wTCF and 4.6 and 10.1 months for wTX, respectively. CONCLUSION: Weekly TCF and TX have encouraging activity and less haematological toxicity than TCF administered 3-weekly. Weekly docetaxel-based combination regimens warrant further evaluation in this disease.

show abstract

“…However, in the neoadjuvant setting, no superiority could be shown for taxanes [16], and no randomized data are available so far. The association of merely platinum-based regimens with clinical response might be influenced by the small subgroups, because normally, higher response rates are expected for triple chemotherapy regimens, especially for taxane-containing regimens [17][18][19][20][21].…”

Section: Discussionmentioning

confidence: 99%

Post-therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation

Blank

Lordick

Bader³

et al. 2014

Gastric Cancer

View full text Add to dashboard Cite

Background Neoadjuvant chemotherapy is an accepted standard of care for locally advanced esophagogastric cancer. As only a subgroup benefits, a response-based tailored treatment would be of interest. The aim of our study was the evaluation of the prognostic and predictive value of clinical response in esophagogastric adenocarcinomas. Methods Clinical response based on a combination of endoscopy and computed tomography (CT) scan was evaluated retrospectively within a prospective database in center A and then transferred to center B. A total of 686/740 (A) and 184/210 (B) patients, staged cT3/4, cN0/1 underwent neoadjuvant chemotherapy and were then restaged by endoscopy and CT before undergoing tumor resection. Of 184 patients, 118 (B) additionally had an interim response assessment 4-6 weeks after the start of chemotherapy. Results In A, 479 patients (70 %) were defined as clinical nonresponders, 207 (30 %) as responders. Median survival was 38 months (nonresponders: 27 months, responders: 108 months, log-rank, p \ 0.001). Clinical and histopathological response correlated significantly (p \ 0.001). In multivariate analysis, clinical response was an independent prognostic factor (HR for death 1.4, 95 %CI 1.0-1.8, p = 0.032). In B, 140 patients (76 %) were nonresponders and 44 (24 %) responded. Median survival was 33 months, (nonresponders: 27 months, responders: not reached, Electronic supplementary material The online version of this article

show abstract

Docetaxel, Cisplatin, and Fluorouracil; Docetaxel and Cisplatin; and Epirubicin, Cisplatin, and Fluorouracil As Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial of the Swiss Group for Clinical Cancer Research

Abstract: Time to response and ORR favor TCF over TC for further evaluation, particularly in the neoadjuvant setting. A trend towards increased myelosuppression and infectious complications with TCF versus TC or ECF was observed.

Cited by 211 publications

References 22 publications

Efficacy of Taxane-Based Regimens in a First-line Setting for Recurrent and/or Metastatic Chinese Patients with Esophageal Cancer

Efficacy of Taxane-Based Regimens in a First-line Setting for Recurrent and/or Metastatic Chinese Patients with Esophageal Cancer

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial

Post-therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation

Contact Info

Product

Resources

About